Completed
Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
NCT00220272
- Conditions
- Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
- Locations
-
- Sanofi-Aventis Administrative Office Laval, Canada
- Sanofi-Aventis Administrative Office Helsinki, Finland
- Sanofi-Aventis Administrative Office Paris, France
- Sanofi-Aventis Administrative Office Gouda, Netherlands